In:
ChemMedChem, Wiley, Vol. 2, No. 6 ( 2007-06-11), p. 841-852
Abstract:
We have recently reported a new class of CDK2/cyclin A inhibitors based on a bicyclic tetrahydropyrrolo[3,4‐c]pyrazole scaffold. The introduction of small alkyl or cycloalkyl groups in position 6 of this scaffold allowed variation at the other two diversity points. Conventional and polymer‐assisted solution phase chemistry provided a way of generating compounds with improved biochemical and cellular activity. Optimization of the physical properties and pharmacokinetic profile led to a compound which exhibited good efficacy in vivo on A2780 human ovarian carcinoma.
Type of Medium:
Online Resource
ISSN:
1860-7179
,
1860-7187
DOI:
10.1002/cmdc.200600302
Language:
English
Publisher:
Wiley
Publication Date:
2007
detail.hit.zdb_id:
2209649-8
SSG:
15,3
Permalink